当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients.

Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients.

Abstract：

:The association between promoter methylation status and survival was investigated in a large cohort of women with breast cancer, participants in the Long Island Breast Cancer Study Project. Archived tumor tissues (n = 839) were collected from women diagnosed with a first primary invasive or in situ breast cancer in 1996-1997. Vital status was followed through the end of 2005 with a mean follow-up time of 8 years. Promoter methylation of eight breast cancer-related genes was assessed by MethyLight. The frequencies of methylation for HIN1, RASSF1A, DAPK1, GSTP1, CyclinD2, TWIST, CDH1 and RARβ were 62.9, 85.2, 14.1, 27.8, 19.6, 15.3, 5.8 and 27.6%, respectively. Since survival rates of in situ and invasive breast cancers are substantially different, survival analyses were conducted within 670 invasive cases with complete data on all genes. Age-adjusted Cox proportional hazards models revealed that GSTP1, TWIST and RARβ methylation was significantly associated with higher breast cancer-specific mortality. Methylation of GSTP1 and RARβ was significantly associated with higher all-cause mortality. To investigate the relationship between the number of methylated genes and breast cancer-specific mortality, we included previously published MethyLight data on p16 and APC methylation status. Breast cancer-specific mortality increased in a dose-dependent manner with increasing number of methylated genes (P (trend) = 0.002), although confidence intervals were wide. Our results suggest that promoter methylation, particularly for a panel of genes, has the potential to be used as a biomarker for predicting prognosis in breast cancer.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Cho YH,Shen J,Gammon MD,Zhang YJ,Wang Q,Gonzalez K,Xu X,Bradshaw PT,Teitelbaum SL,Garbowski G,Hibshoosh H,Neugut AI,Chen J,Santella RM

doi

10.1007/s10549-011-1712-y

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

197-205

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

131

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT.

    abstract：PURPOSE:In rodents, a single exercise bout performed 24 h prior to a single doxorubicin treatment provides cardio-protection. This study investigated whether performing this intervention prior to every doxorubicin treatment for breast cancer reduced subclinical cardiotoxicity and treatment symptoms. METHODS:Twenty-fou...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-017-4554-4

    authors： Kirkham AA,Eves ND,Shave RE,Bland KA,Bovard J,Gelmon KA,Virani SA,McKenzie DC,Stöhr EJ,Waburton DER,Campbell KL

    更新日期：2018-02-01 00:00:00

  • NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.

    abstract：:Resistance to endocrine therapy is a major clinical challenge in current treatment of estrogen receptor-positive breast cancer. The molecular mechanisms underlying resistance are yet not fully clarified. In this study, we investigated whether NFκB signaling is causally involved in antiestrogen resistant cell growth an...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2053-1

    authors： Yde CW,Emdal KB,Guerra B,Lykkesfeldt AE

    更新日期：2012-08-01 00:00:00

  • Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors.

    abstract：PURPOSE:This project was undertaken to examine the association between dietary intake of soy or cruciferous vegetables and breast cancer treatment-related symptoms among Chinese-American (CA) and Non-Hispanic White (NHW) breast cancer survivors. METHODS:This cross-sectional study included 192 CA and 173 NHW female bre...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4578-9

    authors： Nomura SJO,Hwang YT,Gomez SL,Fung TT,Yeh SL,Dash C,Allen L,Philips S,Hilakivi-Clarke L,Zheng YL,Wang JH

    更新日期：2018-04-01 00:00:00

  • Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients.

    abstract：PURPOSE:Breast cancer is a leading cause of cancer deaths in women, but despite steady improvements in therapies, treatment is still suboptimal. Immunotherapy holds promise as a more effective therapy for breast cancer; supporting this, our prior study showed that patients possessing HER2-reactive CD8+ T cells in blood...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-4037-z

    authors： Janssen N,Fortis SP,Speigl L,Haritos C,Sotiriadou NN,Sofopoulos M,Arnogiannaki N,Stavropoulos-Giokas C,Dinou A,Perez S,Pawelec G,Baxevanis CN,Shipp C

    更新日期：2017-01-01 00:00:00

  • C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients.

    abstract：:To investigate the expression levels of CXCL10 and CXCR3 in tumors from breast cancer patients randomized to adjuvant tamoxifen treatment or no endocrine treatment, in order to further study the connection to prognosis and prediction of tamoxifen treatment outcome. Immunohistochemistry on tissue microarrays from 912 b...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-014-2933-7

    authors： Hilborn E,Sivik T,Fornander T,Stål O,Nordenskjöld B,Jansson A

    更新日期：2014-05-01 00:00:00

  • Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients.

    abstract：:Uncontrolled proliferation is one of the hallmarks of breast cancer. We have previously identified the human Ecd protein (human ortholog of Drosophila Ecdysoneless, hereafter called Ecd) as a novel promoter of mammalian cell cycle progression, a function related to its ability to remove the repressive effects of Rb-fa...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1946-8

    authors： Zhao X,Mirza S,Alshareeda A,Zhang Y,Gurumurthy CB,Bele A,Kim JH,Mohibi S,Goswami M,Lele SM,West W,Qiu F,Ellis IO,Rakha EA,Green AR,Band H,Band V

    更新日期：2012-07-01 00:00:00

  • Identification of two novel BRCA1-partner genes in the DNA double-strand break repair pathway.

    abstract：:M1775R and A1789T are two missense variants located within the BRCT domains of BRCA1 gene. The M1775R is a known deleterious variant, while the A1789T is an unclassified variant that has been analyzed and classified as probably deleterious for the first time by our group. In a previous study, we described the expressi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2705-9

    authors： Guglielmi C,Cerri I,Evangelista M,Collavoli A,Tancredi M,Aretini P,Caligo MA

    更新日期：2013-10-01 00:00:00

  • Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.

    abstract：:Familial aggregations of breast/ovarian cancer cases frequently depend on BRCA1/2 pathogenic mutations. Here we counselled 120 Italian breast/ovarian cancer families and selected 73 probands for BRCA1/2 mutation screening. Through this analysis we defined the prevalence of BRCA1/2 pathogenic mutations occurring in Ita...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9225-9

    authors： Giannini G,Capalbo C,Ristori E,Ricevuto E,Sidoni T,Buffone A,Cortesi E,Marchetti P,Scambia G,Tomao S,Rinaldi C,Zani M,Ferraro S,Frati L,Screpanti I,Gulino A

    更新日期：2006-11-01 00:00:00

  • The value of embedding: integrated palliative care for patients with metastatic breast cancer.

    abstract：PURPOSE:The American Society of Clinical Oncology recommends concurrent palliative care (PC) for patients with metastatic cancer. Recent data show benefits of early PC (at least 90 days before death). However, little is known about PC among patients who die from metastatic breast cancer. METHODS:Patients with metastat...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/s10549-017-4556-2

    authors： Rabow M,Small R,Jow A,Majure M,Chien A,Melisko M,Belkora J,Esserman LJ,Rugo H

    更新日期：2018-02-01 00:00:00

  • Intra-operative ultrasound versus wire-guided localization in the surgical management of non-palpable breast cancers: systematic review and meta-analysis.

    abstract：INTRODUCTION:The current standard of treatment for non-palpable breast cancers is wire-guided localization (WGL). WGL has its drawbacks and alternatives such as radio-guided surgery (RGL) and intra-operative ultrasound (IOUS) have been developed. The clinical effectiveness of all forms of RGL has been assessed against ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-013-2639-2

    authors： Ahmed M,Douek M

    更新日期：2013-08-01 00:00:00

  • Molecular determinants of drug response in TNBC cell lines.

    abstract：PURPOSE:There is a need for biomarkers of drug efficacy for targeted therapies in triple-negative breast cancer (TNBC). As a step toward this, we identify multi-omic molecular determinants of anti-TNBC efficacy in cell lines for a panel of oncology drugs. METHODS:Using 23 TNBC cell lines, drug sensitivity scores (DSS3...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05473-9

    authors： Merrill NM,Lachacz EJ,Vandecan NM,Ulintz PJ,Bao L,Lloyd JP,Yates JA,Morikawa A,Merajver SD,Soellner MB

    更新日期：2020-01-01 00:00:00

  • Evaluation of changes to foot shape in females 5 years after mastectomy: a case-control study.

    abstract：PURPOSE:The aim of this study was to evaluate changes in foot shape of women 5 years after undergoing breast amputation. METHODS:Evaluation of foot shape was performed using a non-invasive device for computer analysis of the plantar surface of the foot. Obtained results were compared between feet on the healthy breast...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4183-y

    authors： Głowacka-Mrotek I,Sowa M,Siedlecki Z,Nowikiewicz T,Hagner W,Zegarski W

    更新日期：2017-06-01 00:00:00

  • Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells.

    abstract：:Clinical evidence indicates that higher levels of estrogen receptor beta (ERbeta) predicts improved disease-free and overall survival in patients treated with adjuvant tamoxifen therapy. To better understand the mechanisms in which ERbeta can modulate breast cancer therapies, we introduced ERbeta under an inducible pr...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9640-6

    authors： Hodges-Gallagher L,Valentine CD,El Bader S,Kushner PJ

    更新日期：2008-05-01 00:00:00

  • Diagnostic work-up of contralateral breast cancers has not improved over calendar period.

    abstract：:Women who have been treated for breast cancer are typically followed up with regular mammography and palpation, with the aim of detecting recurrences and contralateral breast cancer (CBC). This study aims to investigate if the diagnostic work-up of breast cancer patients has improved over the last 25 years and resulte...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-0748-8

    authors： Sandberg ME,Hartman M,Edgren G,Eloranta S,Ploner A,Hall P,Czene K

    更新日期：2010-08-01 00:00:00

  • Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.

    abstract：:The present preclinical study was designed to evaluate a new combination therapy comprised of the aromatase inhibitor anastrozole (ANA) and the oral fluoropyrimidines, UFT and S-1 against the estrogen receptor (ER)-positive human breast cancer cell line MCF-7/Arom 14, which was stably transfected with the cDNA of huma...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1141-3

    authors： Nukatsuka M,Saito H,Nakagawa F,Abe M,Uchida J,Shibata J,Matsuo K,Noguchi S,Kiniwa M

    更新日期：2011-07-01 00:00:00

  • Medical costs associated with metastatic breast cancer in younger, midlife, and older women.

    abstract：PURPOSE:We estimated average medical costs due to metastatic breast cancer (mBC) among younger (aged 18-44), midlife (aged 45-64), and older women (aged 65 and older) by phase of care: initial, continuing, and terminal. METHODS:We used 2003-2014 North Carolina cancer registry data linked with administrative claims fro...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05654-x

    authors： Trogdon JG,Baggett CD,Gogate A,Reeder-Hayes KE,Rotter J,Zhou X,Ekwueme DU,Fairley TL,Wheeler SB

    更新日期：2020-06-01 00:00:00

  • Meeting the physical activity guidelines and survival after breast cancer: findings from the after breast cancer pooling project.

    abstract：:The 2008 Physical Activity (PA) Guidelines recommend engaging in at least 2.5 h (10 MET-hours/week) of moderate intensity PA per week (defined as 4 METs) to reduce risk of morbidity and mortality. This analysis was conducted to investigate whether this recommendation can be extended to breast cancer survivors. Data fr...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1770-1

    authors： Beasley JM,Kwan ML,Chen WY,Weltzien EK,Kroenke CH,Lu W,Nechuta SJ,Cadmus-Bertram L,Patterson RE,Sternfeld B,Shu XO,Pierce JP,Caan BJ

    更新日期：2012-01-01 00:00:00

  • Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study.

    abstract：PURPOSE:Evidence suggests that premenopausal obesity decreases and postmenopausal obesity increases breast cancer risk. Because it is not well known whether this is subtype dependent, we studied the association between body mass index (BMI) and age at breast cancer diagnosis, or the probability of being diagnosed with ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4579-8

    authors： Brouckaert O,Van Asten K,Laenen A,Soubry A,Smeets A,Nevelstreen I,Vergote I,Wildiers H,Paridaens R,Van Limbergen E,Weltens C,Moerman P,Floris G,Neven P,Multidisciplinary breast centre Leuven.

    更新日期：2018-02-01 00:00:00

  • Identification of breast cancer-restricted antigens by antibody screening of SKBR3 cDNA library using a preselected patient's serum.

    abstract：:Screening of a breast cancer cDNA library from SKBR3 human breast cancer cells by SEREX (serological analysis of cDNA expression library) using a preselected serum from a breast cancer patient revealed 13 genes, two of which, INT-MI-1 and INT-MI-2, encode novel gene products, while the remaining 11 genes and their pro...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1015854415746

    authors： Forti S,Scanlan MJ,Invernizzi A,Castiglioni F,Pupa S,Agresti R,Fontanelli R,Morelli D,Old LJ,Pupa SM,Ménard S

    更新日期：2002-06-01 00:00:00

  • A two-stage approach to genetic risk assessment in primary care.

    abstract：:Genetic risk prediction models such as BRCAPRO are used routinely in genetic counseling for identification of potential BRCA1 and BRCA2 mutation carriers. They require extensive information on the counselee and her family history, and thus are not practical for primary care. To address this gap, we develop and test a ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3686-2

    authors： Biswas S,Atienza P,Chipman J,Blackford AL,Arun B,Hughes K,Parmigiani G

    更新日期：2016-01-01 00:00:00

  • Loss of BRCA1 expression in sporadic male breast carcinoma.

    abstract：:BRCA1 protein is normally expressed in the nuclei of breast epithelial cells and functions as a negative regulator of the cell cycle. Mutations of BRCA1 gene have been associated with familial breast carcinomas. Although somatic mutations have not been demonstrated in sporadic breast carcinomas, loss of nuclear expres...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1013317909431

    authors： Sun X,Gong Y,Rao MS,Badve S

    更新日期：2002-01-01 00:00:00

  • The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.

    abstract：:The aromatase inhibitors (AIs) are used to treat estrogen receptor-positive (ER+) breast tumors in post-menopausal women, and function by blocking the conversion of adrenal androgens to estrogens by the enzyme CYP19 aromatase. Breast cancer patients receiving AI therapy have circulating estrogen levels below the level...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0080-8

    authors： Sikora MJ,Cordero KE,Larios JM,Johnson MD,Lippman ME,Rae JM

    更新日期：2009-05-01 00:00:00

  • Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).

    abstract：:The aim of this study was to compare the effects on health-related quality of life (HRQOL) of two treatment regimens in the TEX trial during 9 month from random assignment, with emphasis on the 2- and 9-months assessments. A total of 287 patients were randomized to treatment in 3-week cycles with either epirubicin plu...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-010-1084-8

    authors： Svensson H,Einbeigi Z,Johansson H,Hatschek T,Brandberg Y

    更新日期：2010-10-01 00:00:00

  • Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.

    abstract：BACKGROUND:Differences in de novo (dnMBC) and recurrent metastatic breast cancer (rMBC) presentation and survival over time have not been adequately described. METHODS:A retrospective cohort study, 1990-2010, with follow up through 2015 of dnMBC patients (stage IV at diagnosis) and rMBC patients with subsequent distan...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4529-5

    authors： Malmgren JA,Mayer M,Atwood MK,Kaplan HG

    更新日期：2018-01-01 00:00:00

  • PALB2 mutations in German and Russian patients with bilateral breast cancer.

    abstract：:Since germline mutations in the PALB2 (Partner and Localizer of BRCA2) gene have been identified as breast cancer (BC) susceptibility alleles, the geographical spread and risks associated with PALB2 mutations are subject of intense investigation. Patients with bilateral breast cancer constitute a valuable group for ge...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1290-4

    authors： Bogdanova N,Sokolenko AP,Iyevleva AG,Abysheva SN,Blaut M,Bremer M,Christiansen H,Rave-Fränk M,Dörk T,Imyanitov EN

    更新日期：2011-04-01 00:00:00

  • BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research.

    abstract：:The Breast Cancer Family Registry is a resource for interdisciplinary and translational studies of the genetic epidemiology of breast cancer. This resource is available to researchers worldwide for collaborative studies. Herein, we report the results of testing for germline mutations in BRCA1 and BRCA2. We have tested...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0153-8

    authors： Neuhausen SL,Ozcelik H,Southey MC,John EM,Godwin AK,Chung W,Iriondo-Perez J,Miron A,Santella RM,Whittemore A,Andrulis IL,Buys SS,Daly MB,Hopper JL,Seminara D,Senie RT,Terry MB,Breast Cancer Family Registry.

    更新日期：2009-07-01 00:00:00

  • Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.

    abstract：:To investigate the prognostic value of tumor markers, cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) levels at diagnosis of systemic recurrence. After primary treatments of locoregional breast cancers, serum CA 15-3 and/or CEA concentrations were regularly measured, and systemic recurrences were iden...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2695-7

    authors： Lee JS,Park S,Park JM,Cho JH,Kim SI,Park BW

    更新日期：2013-10-01 00:00:00

  • Effects of tea consumption and the interactions with lipids on breast cancer survival.

    abstract：PURPOSE:The effect of tea consumption on breast cancer survival remained to be explored. Meanwhile, green tea favorably facilitates lipid metabolisms in breast cancer survivors. This study aimed to examine the effect of tea consumption and the interactions with lipids on breast cancer survival. METHODS:A total of 1551...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05253-5

    authors： Zhang JY,Liao YH,Lin Y,Liu Q,Xie XM,Tang LY,Ren ZF

    更新日期：2019-08-01 00:00:00

  • Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.

    abstract：:Gene fusions have long been considered principally as the oncogenic events of hematologic malignancies, but have recently gained wide attention in solid tumors due to several milestone discoveries and the advancement of deep sequencing technologies. With the progress in deep sequencing studies of breast cancer transcr...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-016-3876-y

    authors： Veeraraghavan J,Ma J,Hu Y,Wang XS

    更新日期：2016-07-01 00:00:00

  • Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG).

    abstract：:Addition of epirubicin to adjuvant chemotherapy can provide important benefits for patients with early breast cancer, but the optimal dose remains unclear. Further improvements can be achieved with dose-dense regimens, but densification of fluorouracil/epirubicin/cyclophosphamide (FEC) has proved difficult, with FEC(6...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-008-9894-7

    authors： Kahán Z,Spanik S,Wagnerova M,Skacel T,Planko B,Fitzthum E,Lindner E,Soldatenkova V,Zielinski CC,Brodowicz T

    更新日期：2008-12-01 00:00:00